- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Dabrafenib and Trametinib – March 2025
Dabrafenib and Trametinib; Capsule 50 mg (as mesilate), Capsule 75 mg (as mesilate); Tafinlar®; Trametinib, Tablet 500 micrograms, Tablet 2 mg; Mekinist®
Last updated
12 March 2025